MCID: GRD007
MIFTS: 50

Grade Iii Astrocytoma malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Grade Iii Astrocytoma

Aliases & Descriptions for Grade Iii Astrocytoma:

Name: Grade Iii Astrocytoma 12 50 14
Anaplastic Astrocytoma 12 50 56 52 69
Grade Iii Astrocytic Tumor 12

Characteristics:

Orphanet epidemiological data:

56
anaplastic astrocytoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3078
MeSH 42 D001254
NCIt 47 C9477
SNOMED-CT 64 55353007
Orphanet 56 ORPHA251589
UMLS via Orphanet 70 C0334579
ICD10 via Orphanet 34 C71.9
UMLS 69 C0334579

Summaries for Grade Iii Astrocytoma

NIH Rare Diseases : 50 anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. these cells surround and protect nerve cells in the brain and spinal cord. an anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders. treatment may include surgery, radiation, and/or chemotherapy. last updated: 11/3/2014

MalaCards based summary : Grade Iii Astrocytoma, also known as anaplastic astrocytoma, is related to liver fibrosarcoma and wolffian adnexal neoplasm, and has symptoms including headache, seizures and motor manifestations. An important gene associated with Grade Iii Astrocytoma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Temodar and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain and spinal cord, and related phenotypes are Increased cell death HMECs cells and homeostasis/metabolism

Disease Ontology : 12 An astrocytoma that is characterized by cells with regular, round to oval nuclei.

Related Diseases for Grade Iii Astrocytoma

Diseases related to Grade Iii Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
id Related Disease Score Top Affiliating Genes
1 liver fibrosarcoma 10.3 GFAP TP53
2 wolffian adnexal neoplasm 10.3 EGFR TP53
3 cervical adenoid cystic carcinoma 10.3 GFAP TP53
4 clear cell adenofibroma 10.3 CDKN2A TP53
5 testis refractory cancer 10.3 IDH2 TP53
6 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
7 bile duct clear cell adenocarcinoma 10.3 GFAP IDH2 TP53
8 cystinosis, nephropathic 10.3 IDH2 TP53
9 pericardium leiomyoma 10.3 CDKN2A PCNA TP53
10 ophn1 syndrome 10.2 GFAP IDH2 MGMT
11 oro-mandibular-limb hypogenesis syndrome 10.2 CDKN2A PCNA TP53
12 bronchitis 10.2 GFAP TP53
13 brain stem astrocytic neoplasm 10.2 GFAP MGMT TP53
14 acute mountain sickness 10.2 MDM2 TP53
15 cutaneous adenocystic carcinoma 10.2 GFAP MGMT TP53
16 angioma hereditary neurocutaneous 10.2 CDKN2A IDH2 MGMT
17 bronchial mucus gland adenoma 10.2 GFAP IDH2 PTEN
18 spinal cord oligodendroglioma 10.2 CDKN2A PCNA TP53
19 chronic monocytic leukemia 10.2 CDKN2A EGFR TP53
20 thymus squamous cell carcinoma 10.2 CDKN2A EGFR TP53
21 urethral verrucous carcinoma 10.2 CDKN2A PTEN TP53
22 secondary hyperparathyroidism of renal origin 10.2 CDKN2A EGFR TP53
23 allergic contact dermatitis 10.2 CDKN2A EGFR TP53
24 estrogen-receptor positive breast cancer 10.2 CDKN2A EGFR TP53
25 pityriasis rosea 10.2 CDKN2A EGFR TP53
26 pyomyositis 10.2 CDKN2A EGFR TP53
27 spondylarthropathy 10.2 CDKN2A TP53
28 plasmodium ovale malaria 10.2 CDKN2A GFAP TP53
29 pacinian tumor 10.2 CDKN2A GFAP TP53
30 brain oligodendroglioma 10.2 GFAP MDM2 TP53
31 connective tissue benign neoplasm 10.2 CDKN2A EGFR TP53
32 cervical verrucous carcinoma 10.2 CDKN2A MDM2 TP53
33 epimetaphyseal dysplasia cataract 10.2 EGFR GFAP MGMT
34 childhood central nervous system primitive neuroectodermal neoplasm 10.2 GFAP MDM2 TP53
35 gastroesophageal junction adenocarcinoma 10.2 EGFR IDH2 TP53
36 rommen mueller sybert syndrome 10.2 CDK4 MDM2 TP53
37 aneurysm of sinus of valsalva 10.2 GFAP MDM2 PTEN
38 childhood-onset cerebral x-linked adrenoleukodystrophy 10.2 CDKN2A EGFR TP53
39 vascular myelopathy 10.2 CDKN2A MDM2 TP53
40 paroxysmal nocturnal hemoglobinuria 10.2 CDKN2A EGFR TP53
41 pyloric antrum cancer 10.2 PCNA TP53 VEGFA
42 ossifying fibromyxoid tumor 10.2 CDK4 CDKN2A TP53
43 progesterone-receptor positive breast cancer 10.2 CDKN2A EGFR TP53
44 brain stem angioblastoma 10.2 CDK4 MDM2 TP53
45 solitary osseous plasmacytoma 10.2 PTEN VEGFA
46 enchondromatosis dwarfism deafness 10.1 CDK4 MDM2 TP53
47 fallopian tube benign neoplasm 10.1 EGFR GFAP MGMT TP53
48 mediastinum angiosarcoma 10.1 GFAP MDM2 TP53
49 ornithinemia 10.1 CDKN2A EGFR PCNA TP53
50 blood protein disease 10.1 CDK4 GFAP MDM2

Graphical network of the top 20 diseases related to Grade Iii Astrocytoma:



Diseases related to Grade Iii Astrocytoma

Symptoms & Phenotypes for Grade Iii Astrocytoma

UMLS symptoms related to Grade Iii Astrocytoma:


headache, seizures, motor manifestations, sensory manifestations

GenomeRNAi Phenotypes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.1 EGFR MDM2 PCNA PTEN TNC TP53

MGI Mouse Phenotypes related to Grade Iii Astrocytoma:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 CDK4 CDKN2A CDKN2B DMBT1 EGFR GFAP
2 cellular MP:0005384 10.35 PTEN TP53 VEGFA CDK4 CDKN2A CDKN2B
3 immune system MP:0005387 10.34 PDGFRA PTEN TP53 VEGFA CDK4 CDKN2A
4 endocrine/exocrine gland MP:0005379 10.33 PDGFRA PTEN TP53 VEGFA CDK4 CDKN2A
5 cardiovascular system MP:0005385 10.32 CDK4 CDKN2A EGFR GFAP IDH2 MDM2
6 mortality/aging MP:0010768 10.32 CDK4 CDKN2A CDKN2B DMBT1 EGFR GFAP
7 digestive/alimentary MP:0005381 10.3 CDK4 CDKN2A DMBT1 EGFR GFAP MDM2
8 behavior/neurological MP:0005386 10.28 TP53 VEGFA CDK4 CDKN2A GFAP MDM2
9 growth/size/body region MP:0005378 10.28 CDK4 CDKN2A EGFR GFAP MDM2 PCNA
10 hematopoietic system MP:0005397 10.27 VEGFA CDK4 CDKN2A CDKN2B EGFR MDM2
11 neoplasm MP:0002006 10.26 TP53 VEGFA CDK4 CDKN2A CDKN2B DMBT1
12 embryo MP:0005380 10.25 VEGFA CDK4 CDKN2A DMBT1 EGFR MDM2
13 integument MP:0010771 10.2 CDK4 CDKN2A CDKN2B EGFR MDM2 PDGFRA
14 nervous system MP:0003631 10.16 CDK4 CDKN2A EGFR GFAP MDM2 PDGFRA
15 muscle MP:0005369 10.15 CDK4 CDKN2A EGFR GFAP MDM2 PDGFRA
16 no phenotypic analysis MP:0003012 10.13 CDKN2A CDKN2B EGFR MDM2 MGMT PCNA
17 limbs/digits/tail MP:0005371 10.08 PTEN TP53 VEGFA EGFR IDH2 MDM2
18 liver/biliary system MP:0005370 10.07 CDK4 CDKN2A EGFR MDM2 PTEN TP53
19 normal MP:0002873 10.06 CDK4 EGFR GFAP MDM2 PDGFRA PTEN
20 renal/urinary system MP:0005367 9.97 CDK4 CDKN2B DMBT1 EGFR MDM2 PDGFRA
21 reproductive system MP:0005389 9.96 CDKN2B EGFR MDM2 PCNA PDGFRA PTEN
22 pigmentation MP:0001186 9.91 CDK4 CDKN2A EGFR MDM2 PDGFRA PTEN
23 respiratory system MP:0005388 9.7 CDKN2A EGFR MGMT PDGFRA PTEN TP53
24 skeleton MP:0005390 9.56 PDGFRA PTEN TP53 VEGFA CDKN2A EGFR
25 vision/eye MP:0005391 9.17 CDK4 CDKN2A EGFR GFAP PTEN TP53

Drugs & Therapeutics for Grade Iii Astrocytoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Temodar 17 46 TEMOZOLOMIDE Schering-Plough Approved August 1999

Drugs for Grade Iii Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 413)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
2
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
3
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
4
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
7
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
8
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
9
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
10
Levoleucovorin Approved Phase 3,Phase 1 68538-85-2
11
Mechlorethamine Approved Phase 3,Phase 1,Phase 2 51-75-2 4033
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
14
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
15
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
16
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
17
Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
18
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
20
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
21
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
22
Isotretinoin Approved Phase 3,Phase 1,Phase 2 4759-48-2 5538 5282379
23
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
24
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1 216974-75-3
25
Flucytosine Approved Phase 2, Phase 3,Phase 1 2022-85-7 3366
26
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
27
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
28
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
29
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
30
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
31
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
32
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
33
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
34
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
35
Ondansetron Approved Phase 3 99614-02-5 4595
36
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
37
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
38
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
41
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 302-79-4 5538
42 tannic acid Approved, Nutraceutical Phase 3,Phase 2
43
Veliparib Investigational Phase 2, Phase 3,Phase 1 912444-00-9 11960529
44 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
45 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
46 Dermatologic Agents Phase 3,Phase 1,Phase 2
47 Dihematoporphyrin Ether Phase 3,Phase 2,Phase 1
48 Ether Phase 3,Phase 2,Phase 1
49 Photosensitizing Agents Phase 3,Phase 2,Phase 1
50 Antimitotic Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 491)
id Name Status NCT ID Phase
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
2 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3
3 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3
4 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3
5 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
6 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3
7 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3
8 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3
9 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3
10 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3
11 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
12 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3
13 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
15 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
16 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3
17 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3
18 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3
19 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3
20 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3
21 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3
22 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3
23 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3
24 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3
25 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Recruiting NCT00978458 Phase 3
26 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Active, not recruiting NCT00004259 Phase 3
27 P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA Active, not recruiting NCT02414165 Phase 2, Phase 3
28 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3
29 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Active, not recruiting NCT01236560 Phase 2, Phase 3
30 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00003375 Phase 2, Phase 3
31 Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Active, not recruiting NCT00884741 Phase 3
32 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Active, not recruiting NCT00045968 Phase 3
33 Bevacizumab and Lomustine for Recurrent GBM Active, not recruiting NCT01290939 Phase 3
34 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Active, not recruiting NCT01346267 Phase 3
35 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Not yet recruiting NCT03149575 Phase 3
36 Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM Not yet recruiting NCT03008148 Phase 2, Phase 3
37 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Suspended NCT02152982 Phase 2, Phase 3
38 Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma Terminated NCT00761280 Phase 3
39 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
40 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3
41 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3
42 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2
43 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2
44 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2
45 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2
46 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Unknown status NCT00045110 Phase 1, Phase 2
47 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Unknown status NCT00003176 Phase 2
48 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2
49 Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma Unknown status NCT00047281 Phase 2
50 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2

Search NIH Clinical Center for Grade Iii Astrocytoma

Genetic Tests for Grade Iii Astrocytoma

Anatomical Context for Grade Iii Astrocytoma

MalaCards organs/tissues related to Grade Iii Astrocytoma:

39
Brain, Spinal Cord

Publications for Grade Iii Astrocytoma

Articles related to Grade Iii Astrocytoma:

id Title Authors Year
1
Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent Grade III astrocytoma. ( 23391098 )
2013
2
Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. ( 20090216 )
2010
3
Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. ( 16988542 )
2006
4
Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas. ( 9020393 )
1997
5
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report). ( 8899347 )
1996
6
p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. ( 1349850 )
1992

Variations for Grade Iii Astrocytoma

Expression for Grade Iii Astrocytoma

Search GEO for disease gene expression data for Grade Iii Astrocytoma.

Pathways for Grade Iii Astrocytoma

Pathways related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 CDK4 CDKN2A CDKN2B EGFR GFAP MDM2
2
Show member pathways
13.68 CDK4 CDKN2A CDKN2B EGFR MDM2 PDGFRA
3
Show member pathways
13.12 CDK4 CDKN2A CDKN2B MDM2 TP53 VEGFA
4
Show member pathways
13.04 EGFR MDM2 PDGFRA PTEN TNC TP53
5
Show member pathways
12.97 CDK4 CDKN2A CDKN2B EGFR MDM2 PDGFRA
6
Show member pathways
12.93 CDKN2A MDM2 PCNA PTEN TP53
7
Show member pathways
12.87 EGFR PDGFRA PTEN TNC VEGFA
8
Show member pathways
12.72 EGFR MDM2 PDGFRA PTEN TP53
9
Show member pathways
12.67 CDK4 MDM2 MGMT PCNA TP53
10
Show member pathways
12.59 CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
11
Show member pathways
12.55 CDKN2A MDM2 PCNA TP53
12 12.52 CDK4 CDKN2A MDM2 MGMT PCNA TP53
13 12.5 CDK4 EGFR MDM2 PDGFRA PTEN TNC
14
Show member pathways
12.48 EGFR PDGFRA PTEN TP53
15
Show member pathways
12.43 EGFR MDM2 PDGFRA TP53
16 12.43 CDK4 CDKN2A CDKN2B PCNA PDGFRA TP53
17
Show member pathways
12.39 CDK4 CDKN2A MDM2 PTEN TP53
18
Show member pathways
12.38 MDM2 PCNA PTEN TP53
19
Show member pathways
12.38 EGFR MDM2 PCNA PTEN TP53
20 12.36 CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
21
Show member pathways
12.34 CDK4 CDKN2A CDKN2B TP53
22 12.33 CDKN2A EGFR MDM2 PDGFRA PTEN TNC
23 12.32 CDK4 CDKN2A CDKN2B MDM2 TP53
24 12.29 EGFR MDM2 TP53 VEGFA
25
Show member pathways
12.25 CDK4 MDM2 PTEN TP53
26 12.21 CDK4 CDKN2A CDKN2B EGFR MDM2 PDGFRA
27
Show member pathways
12.2 CDK4 EGFR MDM2 PDGFRA PTEN TP53
28 12.16 CDK4 EGFR MDM2 PTEN TP53 VEGFA
29
Show member pathways
12.1 CDKN2B EGFR MDM2 PTEN
30
Show member pathways
12.1 CDK4 CDKN2A EGFR MDM2 TP53 VEGFA
31 12.08 EGFR MDM2 PCNA PTEN TP53
32 12.03 CDK4 EGFR GFAP TP53
33 12.01 CDKN2A MDM2 PTEN TP53
34 11.96 CDKN2A MDM2 PCNA PTEN TP53
35
Show member pathways
11.92 EGFR GFAP MDM2
36 11.88 CDK4 MDM2 PCNA TP53
37 11.85 CDK4 CDKN2B PTEN TP53
38 11.84 EGFR MDM2 PTEN
39 11.83 CDK4 CDKN2A MDM2 MGMT PCNA PTEN
40 11.78 GFAP PDGFRA VEGFA
41 11.73 CDKN2A MDM2 TP53
42
Show member pathways
11.73 CDKN2A MDM2 TP53
43 11.72 EGFR PDGFRA PTEN TP53
44 11.7 CDKN2A MDM2 TP53 VEGFA
45 11.66 CDK4 CDKN2A EGFR MDM2 TP53 VEGFA
46 11.63 CDKN2A MDM2 TP53 VEGFA
47 11.59 MDM2 PTEN TP53
48 11.59 CDKN2A EGFR PDGFRA TP53
49 11.51 CDK4 MDM2 PCNA TP53
50 11.49 CDK4 CDKN2B MDM2 PTEN TP53

GO Terms for Grade Iii Astrocytoma

Biological processes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.91 CDK4 CDKN2A PTEN TP53
2 response to drug GO:0042493 9.91 CDK4 MDM2 MGMT PTEN
3 positive regulation of gene expression GO:0010628 9.83 MDM2 PTEN TNC TP53 VEGFA
4 response to ethanol GO:0045471 9.8 MGMT PTEN TNC
5 response to toxic substance GO:0009636 9.76 CDK4 MDM2 MGMT
6 response to estradiol GO:0032355 9.75 EGFR PCNA PTEN
7 lung development GO:0030324 9.74 EGFR PDGFRA VEGFA
8 wound healing GO:0042060 9.73 EGFR PDGFRA TNC
9 protein sumoylation GO:0016925 9.7 CDKN2A MDM2 PCNA
10 epithelial cell differentiation GO:0030855 9.69 DMBT1 PCNA VEGFA
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.67 MDM2 PCNA TP53
12 positive regulation of fibroblast proliferation GO:0048146 9.65 CDK4 EGFR PDGFRA
13 positive regulation of DNA replication GO:0045740 9.63 EGFR PCNA PDGFRA
14 response to lipid GO:0033993 9.59 EGFR PCNA
15 phosphatidylinositol-mediated signaling GO:0048015 9.56 EGFR PDGFRA PTEN TP53
16 DNA ligation GO:0006266 9.55 MGMT PCNA
17 replicative senescence GO:0090399 9.54 CDKN2A TP53
18 positive regulation of DNA repair GO:0045739 9.5 EGFR MGMT PCNA
19 cellular response to hypoxia GO:0071456 9.46 MDM2 PTEN TP53 VEGFA
20 negative regulation of apoptotic process GO:0043066 9.43 EGFR MDM2 MGMT PTEN TP53 VEGFA
21 cellular response to actinomycin D GO:0072717 9.4 MDM2 TP53
22 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.37 PDGFRA VEGFA
23 positive regulation of cell proliferation GO:0008284 9.17 CDK4 EGFR MDM2 PDGFRA PTEN TNC
24 multicellular organism development GO:0007275 10.08 CDK4 DMBT1 EGFR PDGFRA TP53 VEGFA
25 phosphorylation GO:0016310 10.02 CDK4 CDKN2A CDKN2B EGFR PDGFRA

Molecular functions related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.77 CDK4 CDKN2A CDKN2B EGFR PDGFRA
2 protein kinase binding GO:0019901 9.65 CDKN2A CDKN2B EGFR PTEN TP53
3 enzyme binding GO:0019899 9.55 EGFR MDM2 PCNA PTEN TP53
4 identical protein binding GO:0042802 9.5 EGFR GFAP MDM2 PCNA PTEN TP53
5 SUMO transferase activity GO:0019789 9.4 CDKN2A MDM2
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN2A CDKN2B
7 platelet-derived growth factor receptor binding GO:0005161 8.8 PDGFRA PTEN VEGFA

Sources for Grade Iii Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....